Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Promising Advances in the Mantle Cell Lymphoma Treatment Landscape

02/13/2024

Featuring Eliza A Hawkes, MD

Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.

Eliza A Hawkes, MD, shares some...

02/13/2024

Oncology

Conference Coverage

Assessing Efficacy of Acalabrutinib-Rituximab Followed by Chemo and ASCT for Patients With Treatment-Naive MCL

02/13/2024

Featuring Eliza A Hawkes, MD

Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.

Eliza A Hawkes, MD, shares...

02/13/2024

Oncology

Conference Coverage

Examining Efficacy of Frontline Bendamustine-Rituximab and Second-Line BTK Inhibitor Therapy Among Patients With MCL

01/10/2024

Featuring Yucai Wang, MD, PhD

At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Featuring Bijal D. Shah, MD

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Conference Coverage

Bispecific Lentiviral Anti-CD20/Anti-CD19 CAR T-Cells for R/R MCL

12/21/2023

Featuring Nirav Shah, MD

During the 2023 ASH Annual Meeting in San Diego, Nirav N Shah, MD, discussed the efficacy of dual-targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cells with an adaptive manufacturing process among patients with relapsed/refractory...

During the 2023 ASH Annual...

12/21/2023

Oncology

Conference Coverage

Bendamustine, Rituximab, and Venetoclax Shows Promise Among Previously Untreated Older Patients With MCL

12/21/2023

Featuring Craig A Portell, MD

At the 65th ASH Annual Meeting, Craig A Portell, MD, assessed the potential benefit of bendamustine, rituximab, and venetoclax as an initial treatment among older patients with mantle cell lymphoma, noting that results and safety precautions...

At the 65th ASH Annual Meeting,...

12/21/2023

Oncology

Conference Coverage

Real-World Value of Brexucabtagene Autoleucel for Patients With R/R MCL Including High-Risk Features

12/20/2023

Featuring Swetha Kambhampati, MD

Featuring Swetha Kambhampati, MD ...

At the 65th ASH Annual Meeting, Swetha Kambhampati, MD, shares data on the real-world outcomes of brexucabtagene autoleucel treatment for patients with R/R mantle cell lymphoma, including high-risk subgroups.

At the 65th ASH Annual Meeting,...

12/20/2023

Oncology

Conference Coverage

Assessing the Optimal Ki-67 Cut-Off for Outcome Prediction Among Patients With Newly Diagnosed Mantle Cell Lymphoma

12/10/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...

At the 65th ASH Annual Meeting, Narendranath Epperla, MD, MS, shared insights on an optimal Ki-67 cut-off for patients with newly diagnosed mantle cell lymphoma, which was found to be prognostic for progression-free survival, but not overall...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Videos

Evaluating Prognostic Factors for Mantle Cell Lymphoma

11/15/2023

Featuring Jia Ruan, MD, PhD

Jia Ruan, MD, PhD, discusses important factors to consider in determining mantle cell lymphoma prognosis, including the utilization of measurement tools like MIPI and genetic mutation profile data.

Jia Ruan, MD, PhD, discusses...

11/15/2023

Oncology

Videos

Long-Term Updates on Chemotherapy-Free Lenalidomide Plus Rituximab Treatment for MCL

11/03/2023

Featuring Jia Ruan, MD, PhD

Jia Ruan, MD, PhD, shares 9-year follow-up findings from a phase 2 trial on the outcomes of chemotherapy-free lenalidomide plus rituximab combination therapy among patients with mantle cell lymphoma.

Jia Ruan, MD, PhD, shares 9-year...

11/03/2023

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...

According to interim analysis...

04/25/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...

Based on results from the...

04/25/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Based on results from the...

04/24/2024

Oncology

News

Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma

04/23/2024

Stephanie Holland

Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...

Results from the phase 2 NRG...

04/23/2024

Oncology

News

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/19/2024

Stephanie Holland

Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.

Based on results from the phase...

04/19/2024

Oncology